Objectives: Colorectal cancer (CRC) is the second leading cause of cancer in Europe, with 1.931.590 people newly diagnosed in 2020. The purpose of this study is the investigation of treatment options and healthcare resource metastatic CRC (mCRC) in Greece. Methods: This study is based on the information collected in November 2020 by an expert panel comprising of 6 medical oncologists from major public and private centers around Greece. A 3-round survey was undertaken, according to Delphi method. The treatment phases studied were: pre-progression; disease progression and terminal care. Pharmaceutical costs and resource utilization data were considered from the perspective of the Greek National Services Organization (EOPYY). RESULTS: Experts agreed that the anticipated prevalence of RAS mutation in mCRC is 47% (30% RAS/BRAF WT Left, 17% RAS/BRAF WT Right); 8% BRAF while, MSI-H/dMMR are found in 5% of mCRC tumors. Based on mutational status, 74.8% of patients receive biological targeted therapies in combination with fluoropyrimidine/based combination chemotherapy, as 1st line treatment, and 25.2% combination chemotherapy alone. At 2nd line, 58.6% of patients receive biological targeted therapies in combination with chemotherapy, 25.4% immunotherapy, 11% combination chemotherapy and 5% biological targeted therapies. At 3rd line 56% of patients receive combination chemotherapy, 28% biological targeted therapies, 10% biological targeted therapies in combination with chemotherapy and 6% immunotherapy. The weighted annual cost (pharmaceuticals and resource use cost) in 1st line per mCRC patient was calculated at €28,407, in 2nd line €33,568, in 3rd line €25,550. The annual cost beyond 3rd line per patient regardless mutation was €19,501 per mCRC patient. Conclusions: mCRC is a societal challenge for healthcare systems as the treatment is more prolonged but expand patients’ survival. Thus, reimbursement decisions should be based not just on the cost of the treatment, but on the magnitude of the benefit of its treatment on patients’ survival and quality of life.

Objectives: This study evaluates the economic impact of digital health interventions (DHIs) developed under the HosmartAI EU-funded program, focusing on obstetrics, cardiology, and gastroenterology. Methods: A Cost Consequence Analysis (CCA) was chosen in order to be able to examine the costs and consequences of AI technologies in early diagnosis of preterm births, echocardiography, coronary computed tomography angiography (CCTA), and capsule endoscopy (CE). Results: The results show that in obstetrics and CCTA, the AI technologies are cost-saving, with the AI-based preterm birth detection leading to savings of 99,840 EUR due to reduced severity of prematurity. In the echocardiography scenario, the new AI technology slightly increased costs (9409 vs. 2116 EUR), but offered benefits in diagnostic accuracy and shorter interpretation duration, particularly for less experienced physicians. Similarly, the capsule endoscopy AI technology raised annual costs by 6626 EUR but improved productivity, accuracy, and user satisfaction. Conclusions: The findings emphasize the need for standardized frameworks to guide economic evaluations of DHIs, ensuring informed healthcare investment and reimbursement decisions in the future.